Diabetologia:在40岁以后的糖尿病发病中自身免疫起什么作用?

2020-03-17 MedSci原创 MedSci原创

尽管1型和2型糖尿病在细胞功能、胰岛素抵抗和表型等病理生理因素上存在差异,但可能存在一定的相关性。目前,关于自身免疫与糖尿病发病之间关系的前瞻性研究相对较少。

尽管1型和2型糖尿病在细胞功能、胰岛素抵抗和表型等病理生理因素上存在差异,但可能存在一定的相关性。目前,关于自身免疫与糖尿病发病之间关系的前瞻性研究相对较少。我们在欧洲癌症与营养相互作用前瞻性调查(EPIC)中调查了65 kDa亚型广泛性焦虑症(GAD65)抗体与1型糖尿病和2型糖尿病遗传风险评分和成人糖尿病发病率之间的关系。

通过随机分组(15802例)和突发糖尿病病例(11981例)的放射性结合试验,对EPIC参与者(40岁以上,基线时无已知糖尿病)中的GAD65抗体进行分析。计算1型糖尿病和2型糖尿病的遗传风险评分。用prentice加权Cox回归估计GAD65抗体与糖尿病发病之间的关系。

研究结果显示,对性别,中心,体育活动,吸烟状况和教育程度校正以后,基线GAD65抗体阳性与糖尿病的发展相关,中位随访时间为10.9年(GAD65抗体阳性与阴性的HR为1.78;95% CI 1.43, 2.20) 。在调整年龄和性别后,1型糖尿病的遗传风险评分与亚科(OR每SD遗传风险1.24;95%CI1.03,1.50)和事件病例(OR1.97;95%CI1.72,2.26)的GAD65抗体阳性有关,但2型糖尿病并非如此。与所有其他个体相比,1型糖尿病遗传风险评分中最高也是GAD65抗体阳性的患者发生糖尿病的风险为3.23(95%CI2.10,4.97),这表明发生糖尿病的1.8%归因于这种危险因素的组合。

研究表明,成人糖尿病发病与自身免疫性病因有关。因此,可能需要重新评估目前糖尿病在成年期的亚分类。

原始出处:

Olov RolandssonChristiane S. HampeAutoimmunity plays a role in the onset of diabetes after 40 years of age

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761338, encodeId=7dbb1e613386a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Aug 29 16:52:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639383, encodeId=28751639383b2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 19 17:52:33 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043007, encodeId=dd84104300ee0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Mar 17 17:52:33 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761338, encodeId=7dbb1e613386a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Aug 29 16:52:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639383, encodeId=28751639383b2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 19 17:52:33 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043007, encodeId=dd84104300ee0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Mar 17 17:52:33 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761338, encodeId=7dbb1e613386a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Aug 29 16:52:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639383, encodeId=28751639383b2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 19 17:52:33 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043007, encodeId=dd84104300ee0, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Mar 17 17:52:33 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
    2020-03-17 misszhang

    谢谢MedSci提供最新的资讯

    0